⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2037213 | 0.76 | — | — | |
| SCHEMBL14854005 | 0.76 | — | — | |
| SCHEMBL652516 | 0.76 | — | — | |
| SCHEMBL20059589 | 0.72 | — | — | |
| SCHEMBL5896671 | 0.72 | ALDH1A1 (0.37) | — | |
| SCHEMBL7512631 | 0.72 | PDE10A (0.45) | — | |
| SCHEMBL12641898 | 0.71 | RAB9A (0.46) | — | |
| Formamide SCHEMBL23636189 | 0.71 | ALDH1A1 (0.33) | — | |
| Formic Acid SCHEMBL28512946 | 0.71 | TSHR (0.34) | — | |
| SCHEMBL5399630 | 0.71 | HDAC8 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296938-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2025-09-25 | — | — | US | disclosed |
| EP-4608835-A1 | PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Novo Nordisk A/S (DK) | 2025-09-03 | — | — | EP | disclosed |
| US-12391705-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY THERAPEUTICS, LLC (US) | 2025-08-19 | — | — | US | disclosed |
| CN-120129684-A | Purine compound, composition containing same and use thereof | 诺和诺德股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2024086939-A1 | PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | INVERSAGO PHARMA INC. (CA) | 2024-05-02 | — | — | WO | disclosed |
| US-20230078755-A1 | Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY THERAPEUTICS, LLC | 2023-03-16 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8362265-B2 | Hafnium complexes of heterocyclic organic ligands | DOW GLOBAL TECHNOLOGIES, LLC (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2011072694-A1 | HETEROAROMATIC PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
| US-20090069567-A1 | HAFNIUM COMPLEXES OF HETEROCYCLIC ORGANIC LIGANDS | DOW GLOBAL TECHNOLOGIES LLC | 2009-03-12 | — | — | US | disclosed |